Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 328,436 |
Ending reported balance
After 2026-09-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-03 · Sale · Disposed 7,012 · Balance 341,424 F1: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-03 · Sale · Disposed 6,814 · Balance 334,610 F2: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-03 · Sale · Disposed 6,174 · Balance 328,436 F3: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F2: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 6, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $141.61 | $14,161.00 |
DisclosureSEC source: 0001209191-21-002198 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $140.94 | $126,846.99 |
DisclosureSEC source: 0001209191-21-002198 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.60 to $141.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,200 | $139.88 | $727,385.88 |
DisclosureSEC source: 0001209191-21-002198 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $139.42 to $140.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,300 | $138.91 | $180,587.94 |
DisclosureSEC source: 0001209191-21-002198 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.33 to $139.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 19:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $151.24 | $45,371.01 |
DisclosureSEC source: 0001209191-20-064559 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $151.06 to $151.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 19:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 801 | $149.35 | $119,633.19 |
DisclosureSEC source: 0001209191-20-064559 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,791 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $149.15 to $149.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 19:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,098 | $148.50 | $460,067.87 |
DisclosureSEC source: 0001209191-20-064559 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,592 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $148.10 to $149.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 19:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,200 | $147.68 | $324,904.58 |
DisclosureSEC source: 0001209191-20-064559 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,690 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $147.09 to $148.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 19:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,101 | $146.78 | $161,606.43 |
DisclosureSEC source: 0001209191-20-064559 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,890 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $146.05 to $147.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $153.54 | $138,183.03 |
DisclosureSEC source: 0001209191-20-061715 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $153.34 to $153.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $152.88 | $76,440.00 |
DisclosureSEC source: 0001209191-20-061715 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,891 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $152.24 to $153.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $151.68 | $75,838.00 |
DisclosureSEC source: 0001209191-20-061715 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,391 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $151.59 to $151.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,500 | $150.99 | $528,460.45 |
DisclosureSEC source: 0001209191-20-061715 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,891 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $150.58 to $151.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,100 | $150.15 | $315,306.81 |
DisclosureSEC source: 0001209191-20-061715 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 501,391 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $149.56 to $150.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $136.97 | $150,667.11 |
DisclosureSEC source: 0001209191-20-059384 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $136.77 to $137.20. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,424 | $136.19 | $602,524.91 |
DisclosureSEC source: 0001209191-20-059384 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $135.74 to $136.69. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,576 | $135.41 | $213,400.01 |
DisclosureSEC source: 0001209191-20-059384 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,015 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $134.73 to $135.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $133.18 | $53,270.00 |
DisclosureSEC source: 0001209191-20-059384 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $132.71 to $133.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $139.03 | $69,517.00 |
DisclosureSEC source: 0001209191-20-057070 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $138.33 to $139.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 772 | $137.47 | $106,129.16 |
DisclosureSEC source: 0001209191-20-057070 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $136.96 to $137.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,900 | $136.23 | $531,295.83 |
DisclosureSEC source: 0001209191-20-057070 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,263 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $135.93 to $136.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,328 | $135.62 | $315,722.66 |
DisclosureSEC source: 0001209191-20-057070 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,163 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $134.93 to $135.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,001 | $164.66 | $494,159.36 |
DisclosureSEC source: 0001209191-20-055369 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $164.37 to $165.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,499 | $163.99 | $737,777.06 |
DisclosureSEC source: 0001209191-20-055369 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,492 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $163.31 to $164.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $126.88 | $12,688.00 |
DisclosureSEC source: 0001209191-20-053578 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,999 | $125.99 | $377,832.01 |
DisclosureSEC source: 0001209191-20-053578 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 526,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $125.81 to $126.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,700 | $125.51 | $464,390.33 |
DisclosureSEC source: 0001209191-20-053578 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,090 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $124.81 to $125.79. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 701 | $124.21 | $87,070.79 |
DisclosureSEC source: 0001209191-20-053578 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 532,790 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $123.78 to $124.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $123.48 | $86,433.41 |
DisclosureSEC source: 0001209191-20-050943 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 533,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $123.36 to $123.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,265 | $122.88 | $278,317.31 |
DisclosureSEC source: 0001209191-20-050943 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $122.28 to $123.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 813 | $121.64 | $98,891.29 |
DisclosureSEC source: 0001209191-20-050943 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,456 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $121.19 to $122.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,322 | $120.62 | $400,695.65 |
DisclosureSEC source: 0001209191-20-050943 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,269 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $120.14 to $121.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $119.67 | $47,866.00 |
DisclosureSEC source: 0001209191-20-050943 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $119.00 to $119.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 18:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $115.46 | $11,546.00 |
DisclosureSEC source: 0001209191-20-049524 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 18:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,881 | $114.88 | $216,090.22 |
DisclosureSEC source: 0001209191-20-049524 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.42 to $115.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 18:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,517 | $113.91 | $400,624.99 |
DisclosureSEC source: 0001209191-20-049524 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,972 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $113.42 to $114.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 18:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,002 | $112.96 | $226,143.92 |
DisclosureSEC source: 0001209191-20-049524 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,489 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $112.41 to $113.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 20:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 762 | $105.61 | $80,475.51 |
DisclosureSEC source: 0001209191-20-047038 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $105.45 to $105.79. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 20:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,938 | $104.78 | $622,197.30 |
DisclosureSEC source: 0001209191-20-047038 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,253 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $104.29 to $105.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 20:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $102.99 | $82,388.00 |
DisclosureSEC source: 0001209191-20-047038 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $102.63 to $103.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $100.96 | $30,288.99 |
DisclosureSEC source: 0001209191-20-045162 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $100.48 to $101.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,532 | $99.62 | $252,241.89 |
DisclosureSEC source: 0001209191-20-045162 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,291 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $99.305 to $100.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,668 | $99.08 | $462,515.71 |
DisclosureSEC source: 0001209191-20-045162 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,823 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $98.30 to $99.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $90.15 | $9,015.00 |
DisclosureSEC source: 0001209191-20-042877 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,626 | $89.17 | $323,325.34 |
DisclosureSEC source: 0001209191-20-042877 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $88.84 to $89.50. The price reported above reflects the weighted average sale price. The Repoting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,774 | $88.52 | $334,086.18 |
DisclosureSEC source: 0001209191-20-042877 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,217 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $87.84 to $88.82. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $89.08 | $8,908.00 |
DisclosureSEC source: 0001209191-20-040748 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,896 | $87.99 | $342,792.29 |
DisclosureSEC source: 0001209191-20-040748 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $87.54 to $88.52. The price reported above reflects the weighted average sale price. The Repoting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,504 | $87.08 | $305,112.90 |
DisclosureSEC source: 0001209191-20-040748 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,987 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $86.50 to $87.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 17:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,057 | $90.13 | $95,266.56 |
DisclosureSEC source: 0001209191-20-037674 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $89.99 to $90.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.